BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29855600)

  • 1. Improved grading of IDH-mutated astrocytic gliomas.
    Pirozzi CJ; Yan H
    Nat Rev Neurol; 2018 Jul; 14(7):383-384. PubMed ID: 29855600
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
    Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
    Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker.
    Kurian KM; Haynes HR; Crosby C; Hopkins K; Williams M
    Br J Neurosurg; 2013 Aug; 27(4):442-5. PubMed ID: 23451940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.
    Galbraith K; Garcia M; Wei S; Chen A; Schroff C; Serrano J; Pacione D; Placantonakis DG; William CM; Faustin A; Zagzag D; Barbaro M; Eibl MDPGP; Shirahata M; Reuss D; Tran QT; Alom Z; von Deimling A; Orr BA; Sulman EP; Golfinos JG; Orringer DA; Jain R; Lieberman E; Feng Y; Snuderl M
    Neuro Oncol; 2024 Jun; 26(6):1042-1051. PubMed ID: 38243818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing.
    von Deimling A; Ono T; Shirahata M; Louis DN
    Semin Neurol; 2018 Feb; 38(1):19-23. PubMed ID: 29548048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral heterogeneity of CDKN2A deletions in IDH-mutant astrocytoma.
    Masui K; Onizuka H; Muragaki Y; Kawamata T; Kurata A; Komori T
    Brain Tumor Pathol; 2024 Apr; 41(2):92-95. PubMed ID: 38597998
    [No Abstract]   [Full Text] [Related]  

  • 7. High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas.
    Huse JT; Nafa K; Shukla N; Kastenhuber ER; Lavi E; Hedvat CV; Ladanyi M; Rosenblum MK
    Acta Neuropathol; 2011 Sep; 122(3):367-9. PubMed ID: 21755347
    [No Abstract]   [Full Text] [Related]  

  • 8. Mitotic index is (still) important for grading isocitrate dehydrogenase (IDH)-mutant astrocytoma.
    Roberts KF; Dahiya SM
    Neuro Oncol; 2023 Aug; 25(8):1450-1451. PubMed ID: 37097042
    [No Abstract]   [Full Text] [Related]  

  • 9. CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
    Ranade M; Epari S; Shetty O; Dhanavade S; Chavan S; Sahay A; Sahu A; Shetty P; Moiyadi A; Singh V; Dasgupta A; Chatterjee A; Kannan S; Gupta T
    J Neurooncol; 2024 Mar; 167(1):189-198. PubMed ID: 38265748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma.
    Wijnenga MMJ; French PJ; Dubbink HJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Fleischeuer R; Dirven CMF; Vincent AJPE; van den Bent MJ
    J Neurooncol; 2018 Sep; 139(2):349-357. PubMed ID: 29663171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical Statistics Unlock the Gateway to Further Research: Using Deep Learning to Predict CDKN2A/B Homozygous Deletion in Isocitrate Dehydrogenase-Mutant Astrocytoma.
    Takahashi K; Usuzaki T; Inamori R
    Korean J Radiol; 2023 Dec; 24(12):1303-1305. PubMed ID: 38016690
    [No Abstract]   [Full Text] [Related]  

  • 12. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.
    Brat DJ; Aldape K; Colman H; Figrarella-Branger D; Fuller GN; Giannini C; Holland EC; Jenkins RB; Kleinschmidt-DeMasters B; Komori T; Kros JM; Louis DN; McLean C; Perry A; Reifenberger G; Sarkar C; Stupp R; van den Bent MJ; von Deimling A; Weller M
    Acta Neuropathol; 2020 Mar; 139(3):603-608. PubMed ID: 31996992
    [No Abstract]   [Full Text] [Related]  

  • 13. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
    Brat DJ; Aldape K; Colman H; Holland EC; Louis DN; Jenkins RB; Kleinschmidt-DeMasters BK; Perry A; Reifenberger G; Stupp R; von Deimling A; Weller M
    Acta Neuropathol; 2018 Nov; 136(5):805-810. PubMed ID: 30259105
    [No Abstract]   [Full Text] [Related]  

  • 14. Utility of real-time polymerase chain reaction for the assessment of CDKN2A homozygous deletion in adult-type IDH-mutant astrocytoma.
    Shimizu Y; Suzuki M; Akiyama O; Ogino I; Matsushita Y; Satomi K; Yanagisawa S; Ohno M; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Kondo A
    Brain Tumor Pathol; 2023 Apr; 40(2):93-100. PubMed ID: 36788155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression Analysis of Genes Involved in the RB/E2F Pathway in Astrocytic Tumors.
    Ferreira WA; Araújo MD; Anselmo NP; de Oliveira EH; Brito JR; Burbano RR; Harada ML; Borges Bdo N
    PLoS One; 2015; 10(8):e0137259. PubMed ID: 26317630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.
    Zhang M; Pan Y; Qi X; Liu Y; Dong R; Zheng D; Chang Q; Zhang J; Fang W; Zhong Y
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):101-107. PubMed ID: 27258564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astrocytic gliomas: characterization on a molecular genetic basis.
    von Deimling A; Louis DN; Schramm J; Wiestler OD
    Recent Results Cancer Res; 1994; 135():33-42. PubMed ID: 8047695
    [No Abstract]   [Full Text] [Related]  

  • 18. CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas.
    Hickman RA; Gedvilaite E; Ptashkin R; Reiner AS; Cimera R; Nandakumar S; Price A; Vanderbilt C; Fahy T; Young RJ; Miller AM; Mellinghoff IK; Rosenblum MK; Ladanyi M; Arcila ME; Zhang Y; Brannon AR; Bale TA
    Acta Neuropathol; 2023 Dec; 146(6):845-847. PubMed ID: 37831210
    [No Abstract]   [Full Text] [Related]  

  • 19. Pilocytic astrocytoma: a review of genetic and molecular factors, diagnostic and prognostic markers.
    Bikowska-Opalach B; Szlufik S; Grajkowska W; Jozwiak J
    Histol Histopathol; 2014 Oct; 29(10):1235-48. PubMed ID: 24554201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression.
    Grau SJ; Hampl JA; Kohl AC; Timmer M; Duval IV; Blau T; Ruge MI; Goldbrunner RH
    World Neurosurg; 2017 Jul; 103():180-185. PubMed ID: 28377251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.